479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
Titel:
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
Auteur:
Fernandez, E. Elez Garralda, E. Parikh, A. Italiano, A. Hollebecque, A. Marabelle, A. Friedman, C. Sullivan, R. Tschernia, N. Juarez, M.M. Herrera He, K. Bilusic, M. Trujillo, M. Pedregal Su, Z. Liu, K. Kopetz, S. Gulley, J. Siu, L.L. Ducreux, M.P. Tabernero, J.